Effects of Semaglutide on Body Composition and GFR
Clinical Journal of the American Society of Nephrology · 2026
DOI: 10.2215/cjn.0000001051 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Journal of the American Society of Nephrology, 2026. Verfasst von Hiddo J L Heerspink und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Hauptthemen laut MEDLINE: Body Composition, Glomerular Filtration Rate, Glucagon-Like Peptides, Hypoglycemic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Novo Nordisk.
Abstract (Originalsprache)
Key Points Treatment with semaglutide compared with placebo for 24 weeks reduced lean body mass and fat mass in adults with CKD and overweight or obesity. Changes in lean body mass or fat mass during semaglutide treatment did not correlate with changes in creatinine or cystatin C‑eGFR or measured GFR. Semaglutide significantly reduced extracellular water and BP, and changes in BP correlated with extracellular water.
Background
The glucagon-like peptide-1 receptor agonist semaglutide reduces hemoglobin A1c, body weight, BP, and GFR decline. Semaglutide may influence serum creatinine and cystatin C levels by nonkidney-related mechanisms and thereby affect eGFR. We studied the relationship between changes in body composition, eGFR and measured GFR (mGFR), and BP during semaglutide treatment.
Methods
We performed a prespecified analysis of a randomized placebo-controlled double-blind clinical trial in 101 adults with CKD with overweight status or obesity and without type 2 diabetes. Participants were randomized to 24 weeks of semaglutide 2.4 mg/wk subcutaneously or matched placebo treatment. We measured GFR with iohexol clearance, estimated GFR with creatinine and cystatin C, and used bioimpedance spectroscopy to determine lean body mass, fat mass, and extracellular water.
Results
After 24 weeks of treatment, semaglutide compared with placebo changed total body weight, lean body mass, and fat mass by −9.1 (95% confidence interval [CI], −11.0 to −7.2), −2.5 (95% CI, −6.6 to 1.6), and −3.9 (95% CI, −7.8 to 0.0) kg, respectively. No correlations were present between changes in total body weight, lean body mass, and fat mass with changes in eGFR (creatinine or cystatin C) or mGFR during semaglutide treatment (all Spearman correlation coefficients
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
- The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
- Department of Nephrology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Research, Barcelona, Spain.
- Nephrology Service Hospital Ribera-Polusa Lugo, Lugo, Spain.
- Department of Nephrology, Hospital Universitari Bellvitge, Bellvitge Biomedical Research Institute, University of Barcelona, Barcelona, Spain.
- Department of Nephrology, University Clinical Hospital, INCLIVA, University of Valencia, Valencia, Spain.
ORCID-Profile: Hiddo J L Heerspink, Maria Soler, Jelle M Beernink, Niels Jongs, Josep M Cruzado, Ellen Apperloo, Femke Waanders, Gozewijn D Laverman, Annemarie van der Aart-van der Beek, André P van Beek, Sofia B Ahmed, Roland E Schmieder, Christoph Wanner, José L Górriz
Förderung
- Novo Nordisk
Zitieren
APA
Heerspink, H. J. L., Soler, M., Beernink, J. M., Jongs, N., Cigarran, S., Cruzado, J. M., Puchades, M. J., López-Martínez, M., Apperloo, E., Waanders, F., Laverman, G. D., van der Aart-van der Beek, A., van Beek, A. P., Verhave, J. C., Ahmed, S. B., Schmieder, R. E., Wanner, C., Cherney, D. Z. I., & Górriz, J. L. (2026). Effects of Semaglutide on Body Composition and GFR. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.0000001051
Vancouver
Heerspink HJL, Soler M, Beernink JM, Jongs N, Cigarran S, Cruzado JM, et al. Effects of Semaglutide on Body Composition and GFR. Clinical Journal of the American Society of Nephrology. 2026. doi:10.2215/cjn.0000001051
BibTeX
@article{Heerspink2026,
author = {Heerspink, Hiddo J L and Soler, Maria and Beernink, Jelle M and Jongs, Niels and Cigarran, Secundino and Cruzado, Josep M and Puchades, Maria Jesús and López-Martínez, Marina and Apperloo, Ellen and Waanders, Femke and Laverman, Gozewijn D and van der Aart-van der Beek, Annemarie and van Beek, André P and Verhave, Jacobien C and Ahmed, Sofia B and Schmieder, Roland E and Wanner, Christoph and Cherney, David Z I and Górriz, José L},
title = {Effects of Semaglutide on Body Composition and GFR},
journal = {Clinical Journal of the American Society of Nephrology},
year = {2026},
doi = {10.2215/cjn.0000001051}
}
EUVIMED